DNA, Viral Vector - Adeno
HIV-MAG +GENEVAX® IL-12, Ad35-GRIN/ENV
Kenya AIDS Vaccine Initiative-Kangemi, Kenya; Projet San Francisco-Kigali, Rwanda; Uganda Virus Research Institute-IAVI, Entebbe, Uganda; Profectus BioSciences Inc.; Ichor Medical Systems.
The study is a randomized, double-blind placebo-controlled trial assessing the safety and immunogenicity of a multi-antigen HIV (HIV-MAG) plasmid DNA (pDNA) vaccine co-administered with recombinant human IL-12 pDNA (GENEVAX® IL-12) given intramuscularly by in vivo electroporation (IM/EP) using the Ichor Medical Systems TriGrid Delivery System (TDS-IM), followed or preceded by recombinant Ad35-GRIN/ENV HIV vaccine. This study will recruit HIV-uninfected, healthy volunteers. Approximately 75 volunteers (60 vaccine/15 placebo recipients) will be included in the study.